Strategies helps businesses and individuals solve the complexities of dealing with the government at every level. Our team of specialists concentrate exclusively on government affairs, representing clients nationwide who need assistance with public policy, advocacy, and government relations strategies.
This unique program provides innovative and affordable opportunities to startups and early-stage emerging companies with a solid technology or scientific foundation. We help companies that have a quality management team in place and do not have other significant legal representation.
eMerge’s lawyers and technologists work together to deliver strategic end-to-end eDiscovery and data management solutions for litigation, investigations, due diligence, and compliance matters. We help clients discover the information necessary to resolve disputes, respond to investigations, conduct due diligence, and comply with legal requirements.
Chris Willis, co-leader of Troutman Pepper’s Consumer Financial Services Regulatory Practice Group, was quoted in the Law360 article, “CFPB Plans to Dust off ‘Dormant’ Nonbank Oversight Powers.”
“People generally seem to think it will be directed at fintechs or tech companies, but what they’ve done legally isn’t limited to any particular industry or product type,” said Chris J. Willis, a Troutman Pepper partner and co-leader of the firm’s consumer financial services regulatory practice. “It could be used on an auto title lender or a payment processor, too.”
Because the CFPB must make firm-specific determinations to invoke this exam authority, it’s not an especially efficient means of expanding its oversight jurisdiction, Willis added. Still, if the agency does want to start examining a particular company, he said it could be tough for that nonbank to challenge that decision.
“The bottom line is there’s not a lot to litigate when this happens, because the bureau hasn’t taken any action other than to say it’s going to conduct an examination in the future,” Willis said.
…
But Willis, Kaplinsky, and other attorneys noted the CFPB could face particular resistance from nonbanks to the accompanying plans it unveiled for public disclosure of risk determinations. That’s because, to consumers, those determinations might look like findings of wrongdoing on the part of companies the agency deems risky enough to warrant examination.
…
That perception could also be hard to combat. If a company in this situation were to be examined and given a spotless report card, for example, CFPB regulations would prohibit it from publicizing those findings, according to Willis.
“They get tagged with the stigma of it, but then they can never say anything else about it, regardless of how the exam comes out,” he said.
This just in
Speaking Engagements
SOLID Atlanta 2026
November 5, 2026
800 Spring Street NW, Atlanta, GA 30308
Sponsored Events
11th Annual Philadelphia Fund Alliance Gala – Troutman Pepper Locke
November 5, 2026 | 5:30 PM – 8:30 PM ET
The Rittenhouse Hotel
Philadelphia, PA
Sponsored Events
The American Society for Pharmacy Law’s (ASPL) 2026 Developments in Pharmacy Law Conference
November 5 – 7, 2026
The Hilton Austin
500 E. Fourth Street, Austin, TX 78701
Sponsored Events
Life Sciences Pennsylvania (LSPA) 2026 CEO & CFO Dinner
November 4, 2026 | 5:30 PM – 8:30 PM ET
St. David's Golf Club
845 Radnor Street Rd, Wayne, PA 19087
